Literature DB >> 24681953

Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation.

M Girardot1, C Pecquet2, I Chachoua2, J Van Hees2, S Guibert3, A Ferrant4, L Knoops5, E J Baxter6, P A Beer6, S Giraudier7, R Moriggl8, W Vainchenker9, A R Green6, S N Constantinescu2.   

Abstract

STAT (Signal Transducer and Activator of Transcription) transcription factors are constitutively activated in most hematopoietic cancers. We previously identified a target gene, LPP/miR-28 (LIM domain containing preferred translocation partner in lipoma), induced by constitutive activation of STAT5, but not by transient cytokine-activated STAT5. miR-28 exerts negative effects on thrombopoietin receptor signaling and platelet formation. Here, we demonstrate that, in transformed hematopoietic cells, STAT5 and p53 must be synergistically bound to chromatin for induction of LPP/miR-28 transcription. Genome-wide association studies show that both STAT5 and p53 are co-localized on the chromatin at 463 genomic positions in proximal promoters. Chromatin binding of p53 is dependent on persistent STAT5 activation at these proximal promoters. The transcriptional activity of selected promoters bound by STAT5 and p53 was significantly changed upon STAT5 or p53 inhibition. Abnormal expression of several STAT5-p53 target genes (LEP, ATP5J, GTF2A2, VEGFC, NPY1R and NPY5R) is frequently detected in platelets of myeloproliferative neoplasm (MPN) patients, but not in platelets from healthy controls. In conclusion, persistently active STAT5 can recruit normal p53, like in the case of MPN cells, but also p53 mutants, such as p53 M133K in human erythroleukemia cells, leading to pathologic gene expression that differs from canonical STAT5 or p53 transcriptional programs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24681953      PMCID: PMC4924606          DOI: 10.1038/onc.2014.60

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Critical requirement for Stat5 in a mouse model of polycythemia vera.

Authors:  Dongqing Yan; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

Review 2.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.

Authors:  Christian Pecquet; Carmen C Diaconu; Judith Staerk; Michael Girardot; Caroline Marty; Yohan Royer; Jean-Philippe Defour; Alexandra Dusa; Rodolphe Besancenot; Stephane Giraudier; Jean-Luc Villeval; Laurent Knoops; Pierre J Courtoy; William Vainchenker; Stefan N Constantinescu
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

5.  JAK signaling globally counteracts heterochromatic gene silencing.

Authors:  Song Shi; Healani C Calhoun; Fan Xia; Jinghong Li; Long Le; Willis X Li
Journal:  Nat Genet       Date:  2006-08-06       Impact factor: 38.330

6.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

7.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

8.  JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.

Authors:  M Nakatake; B Monte-Mor; N Debili; N Casadevall; V Ribrag; E Solary; W Vainchenker; I Plo
Journal:  Oncogene       Date:  2011-07-25       Impact factor: 9.867

9.  Acetylation and sumoylation control STAT5 activation antagonistically.

Authors:  Oliver H Krämer; Richard Moriggl
Journal:  JAKSTAT       Date:  2012-07-01

10.  JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors:  Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal:  Nature       Date:  2009-09-27       Impact factor: 49.962

View more
  14 in total

1.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

Review 2.  Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.

Authors:  Xavier Cahu; Stefan N Constantinescu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Authors:  Anna Orlova; Bettina Wingelhofer; Heidi A Neubauer; Barbara Maurer; Angelika Berger-Becvar; György Miklós Keserű; Patrick T Gunning; Peter Valent; Richard Moriggl
Journal:  Expert Opin Ther Targets       Date:  2017-11-24       Impact factor: 6.902

4.  Epigenetic silencing of LPP/miR-28 in multiple myeloma.

Authors:  Zhenhai Li; Kwan Yeung Wong; Godfrey Chi-Fung Chan; Chor Sang Chim
Journal:  J Clin Pathol       Date:  2017-08-03       Impact factor: 3.411

5.  O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.

Authors:  P Freund; M A Kerenyi; M Hager; T Wagner; B Wingelhofer; H T T Pham; M Elabd; X Han; P Valent; F Gouilleux; V Sexl; O H Krämer; B Groner; R Moriggl
Journal:  Leukemia       Date:  2017-01-11       Impact factor: 11.528

6.  Twins with different personalities: STAT5B-but not STAT5A-has a key role in BCR/ABL-induced leukemia.

Authors:  Sebastian Kollmann; Eva Grundschober; Barbara Maurer; Wolfgang Warsch; Reinhard Grausenburger; Leo Edlinger; Jani Huuhtanen; Sabine Lagger; Lothar Hennighausen; Peter Valent; Thomas Decker; Birgit Strobl; Mathias Mueller; Satu Mustjoki; Andrea Hoelbl-Kovacic; Veronika Sexl
Journal:  Leukemia       Date:  2019-01-24       Impact factor: 11.528

7.  Enhancement of myogenic differentiation and inhibition of rhabdomyosarcoma progression by miR-28-3p and miR-193a-5p regulated by SNAIL.

Authors:  Klaudia Skrzypek; Artur Nieszporek; Bogna Badyra; Małgorzata Lasota; Marcin Majka
Journal:  Mol Ther Nucleic Acids       Date:  2021-04-20       Impact factor: 8.886

8.  Chronic Inhibition of STAT3/STAT5 in Treatment-Resistant Human Breast Cancer Cell Subtypes: Convergence on the ROS/SUMO Pathway and Its Effects on xCT Expression and System xc- Activity.

Authors:  Katja Linher-Melville; Mina G Nashed; Robert G Ungard; Sina Haftchenary; David A Rosa; Patrick T Gunning; Gurmit Singh
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

Review 9.  Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer.

Authors:  Bettina Wingelhofer; Heidi A Neubauer; Peter Valent; Xiaonan Han; Stefan N Constantinescu; Patrick T Gunning; Mathias Müller; Richard Moriggl
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

10.  Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial.

Authors:  Weiguo Zhang; Charlie Ly; Jo Ishizawa; Hong Mu; Vivian Ruvolo; Sharon Shacham; Naval Daver; Michael Andreeff
Journal:  Haematologica       Date:  2018-05-17       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.